Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML — Stella

Recruiting

Back to Acute Myeloid Leukemia With FLT3/ITD Mutation trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Moffitt Cancer Center, Tampa, Florida

Key details

Phase

Early testing

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

Jazz Pharmaceuticals

Enrollment target

~22 participants

Started

February 2022

Primary completion

February 2027

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov